Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GRANT OF SHARE OPTIONS

The Board announces that on 6 January 2014, 282,600,000 Options to subscribe for Shares were granted, subject to acceptance of the grantees, under the share option scheme of the Company adopted on 27 December 2012.
This announcement is made pursuant to Rule 17.06A of the Rules (the ''Listing Rules'') Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the

''Stock Exchange'').

The board (the ''Board'') of directors (the ''Directors'') of Hua Han Bio-Pharmaceutical Holdings Limited (the ''Company'') announces that on 6 January 2014, 282,600,000 share options (the ''Options'') to subscribe for ordinary shares of HK$0.10 each of the Company (the ''Shares'') were granted, subject to acceptance of the grantees, under the share option scheme of the Company adopted on 27 December 2012.
The following are the details of the Options granted: Date of grant : 6 January 2014
Exercise price of
Options granted
: Each Option shall entitle the holder of the Option to subscribe for one Share upon exercise of such Option at an exercise price of HK$1.60 per Share, which is the highest of:
(a) the closing price of HK$1.60 per Share as stated in the Stock Exchange's daily quotations sheets on the date of grant; (b) the average closing price of HK$1.54 per Share as stated in the Stock Exchange's daily quotations sheets for the five trading days immediately preceding the date of grant; and (c) the nominal value of a Share of HK$0.10
Number of Options granted
: 282,600,000 Options

- 1 -

Closing price of the Shares on the date of grant
: HK$1.60 per Share
Validity period of the
Options
: The Options shall be exercisable during the period of two years from the date of grant (i.e. from 6 January 2014 to 5 January
2016)
Among the 282,600,000 Options, 27,000,000 Options were granted to the Directors. Details of the Options granted to the Directors are as follows:

Name of Directors

Zhang Peter Y. (Note)

Position

Executive Director and Chairman

Number of Options

3,000,000

Deng Jie

Executive Director

3,000,000

Long Xian Feng

Executive Director

3,000,000

Zhou Chong Ke

Executive Director

3,000,000

Wee Ee Lim

Non-executive Director

3,000,000

Tarn Sien Hao

Non-executive Director

3,000,000

Kung Hsiang Fu

Independent non-executive Director

3,000,000

Tso Wung Wai

Independent non-executive Director

3,000,000

Hon Yiu Ming Matthew

Independent non-executive Director

3,000,000

Note: Mr Zhang Peter Y. is an associate of a substantial shareholder of the Company.

The grant of Options to each of the above Directors has been approved by the independent non-executive Directors (with each of the independent non-executive Director abstaining from voting in respect of the grant of the Options to himself).
Save as disclosed in this announcement, none of grantees of the Options is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.
By order of the Board of
Hua Han Bio-Pharmaceutical Holdings Limited
Zhang Peter Y.

Chairman

Hong Kong, 6 January 2014

As at the date of this announcement, the Board comprises Mr. Zhang Peter Y., Mr. Deng Jie, Mr. Long Xian Feng and Mr. Zhou Chong Ke as executive Directors, Mr. Wee Ee Lim (Ms. Lim Seok Bin Zann as his alternate) and Mr. Tarn Sien Hao as non-executive Directors, and Professor Kung Hsiang Fu, Professor Tso Wung Wai and Mr. Hon Yiu Ming Matthew as independent non-executive Directors.

- 2 -

distributed by